AKT1 and neoplasm: The effects of fisetin bioactive ingredient in SKOV‐3/PAX cells in a dose‐dependent manner are associated with suppressing tumor growth, the cleavage of caspase‐9, caspase‐8, and caspase‐3, and PARP as well as enhanced the sub‐G1 phase and lowered AKT phosphorylation (Choi et al., 2016).